Core Insights - The article emphasizes the increasing attention and efforts towards rare disease treatment in China, highlighting the government's initiatives and the role of international pharmaceutical companies in improving drug accessibility for patients [2][4][10]. Government Initiatives - The Chinese government has been enhancing the rare disease prevention and treatment system, with the first batch of 121 rare diseases and treatment guidelines released in 2018 [2]. - By 2025, the new national medical insurance drug list will add 13 rare disease medications, covering over 90 types of rare disease drugs, significantly reducing the financial burden on patients [2][4]. - As of the end of 2023, 165 rare disease drugs have been approved in China, covering 92 types of rare diseases [4]. Pharmaceutical Industry Engagement - Multinational pharmaceutical companies, such as AstraZeneca, are actively participating in events like the China International Import Expo (CIIE) to showcase their rare disease drugs, which have been approved in China [2][3]. - AstraZeneca has established a company in Qingdao specifically for the import of rare disease medications, indicating a commitment to the Chinese market [3]. Challenges in Treatment - The article outlines significant challenges faced by rare disease patients, including difficulties in diagnosis, lack of effective treatment options, and high drug costs [3][4][6]. - Currently, only 5% of known rare diseases have effective treatments, leaving many patients without options [4][9]. Insurance and Financial Support - Approximately 100 rare disease medications are included in the national medical insurance drug list, covering 42 types of rare diseases, but patients still face out-of-pocket expenses [4][6]. - The government is encouraged to further reduce the self-payment ratio for rare disease drugs and explore innovative insurance solutions to alleviate financial burdens on patients [6][7]. Collaborative Efforts - The establishment of a rare disease collaboration network involving 419 hospitals aims to improve diagnosis and treatment through a multidisciplinary approach [5][8]. - AstraZeneca supports the establishment of rare disease centers of excellence in provinces to enhance patient referral and diagnosis processes [8]. Future Directions - The article calls for the establishment of an innovative drug fund to support cutting-edge treatments for rare diseases, independent of the standard insurance system [7]. - Continuous policy updates and market innovations are expected to enhance the accessibility and affordability of rare disease medications in China [10][11].

Group 1: Core Insights - The annual China International Import Expo (CIIE) accelerates the transformation of global innovative products into commodities, catering to the increasing personalized demands of the public [1] - Novo Nordisk showcased its long-term weight management product, Ozempic, at the expo, emphasizing a comprehensive approach to weight management that includes cognitive enhancement and long-term care [1] - Sanofi's innovative drug, Trelagliptin, received approval for use in China, marking a significant advancement in the treatment of Type 1 diabetes, transitioning from passive to proactive intervention [2] Group 2: Company Developments - Novo Nordisk's Ozempic was launched in China within a week of its first appearance at the previous CIIE, highlighting the rapid commercialization of innovative healthcare solutions [1] - Sanofi is focusing on Type 1 diabetes as a strategic priority, with ongoing research to expand treatment options for both adults and children [2] - AstraZeneca has successfully launched three innovative rare disease drugs in China, with multiple indications now included in the national medical insurance directory [3] Group 3: Market Trends - The demand for eye health products among the aging population in China is becoming increasingly diverse and personalized, moving beyond basic vision correction [3][4] - Alcon is committed to localizing production and accelerating the introduction of innovative eye care products in China, reflecting the country's strategic importance in its global growth [4]